For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Insulin degludec - Diabetes Mellitus
PAD Profile : Insulin degludec - Diabetes Mellitus
Traffic Light Status
Status 1 of 2.
- Not Specified
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
MHRA Safety Alert
Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site. Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.
Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below
The PCN recommends the use of Insulin Degludec (Tresiba®) in line with the policy statements below - see separate policy statements for Type I and Type II below.
Insulin Degludec (Tresiba®) will be considered as BLUE (without an information sheet) on the traffic light system.
Note added January 2025 - Prescribe on specialist recommendation only
Important - Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed - see MHRA Safety Update (below) for key points and practical information.